Today, an FDA advisory committee voted in favor of the benefit/risk profile for our #multiplemyeloma therapy in an earlier line setting in partnership with Bristol Myers Squibb. Learn more here: bit.ly/3TACZWu Today’s outcome highlights the clinical benefit of our CAR T cell therapy and reinforces our commitment to bringing potentially transformative treatment options to more patients.
Congrats to the 2seventy bio team for getting this over the finish line!
Such great news! Congrats to the entire 2Seventy team
Congratulations!
Congratulations.
CSO, Moonlight Bio
7moCongrats to the 2seventy team! Especially for the PATIENTS FIRST trial design allowing for crossover. Of course 3 reviewers didn’t get it, so they can go sip their Friday evening cocktails in shame for incentivizing trials that place patients at known risk for the glory of a prettier survival curve. Unbelievable.